Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study

被引:9
|
作者
Silvestri, Michela [1 ,2 ]
Marando, Francesca [3 ]
Costanzo, Anna Maria [3 ]
Paparatti, Umberto di Luzio [3 ]
Rossi, Giovanni A. [1 ,2 ]
机构
[1] Ist Giannina Gaslini, Pediat Pulmonol & Allergy Unit, I-16148 Genoa, Italy
[2] Ist Giannina Gaslini, Cyst Fibrosis Ctr, I-16148 Genoa, Italy
[3] AbbVie, Dept Med, Latina, Italy
关键词
Acute lower respiratory tract infection; Bronchiolitis; Gestational age; RISK-FACTORS; YOUNG-CHILDREN; UNITED-STATES; INFECTION; BRONCHIOLITIS; DISEASE; POPULATION; ADMISSIONS; BORN; CARE;
D O I
10.1186/s13052-016-0252-9
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Due to different social and epidemiological factors, the eligibility criteria to receive palivizumab prophylaxis may be different between countries, especially in "otherwise healthy" late preterm infants. Methods: We analyzed an Italian database of young children referred to emergency departments for acute lower respiratory tract infection (ALRI) during the RSV season over a four year period, when the use of palivizumab as prophylaxis for RSV disease was not widespread in premature infants. The demographic and environmental characteristics and the RSV positivity (RSV+) in hospitalized and not-hospitalized patients were compared. In the data analysis we divided children according to their chronologic age (age) and their week gestational age (wGA). Results: Out of the 100 children evaluated, 68 were infants (<= 12 month-age): 7.5 and 20.6 % were in the <29 and 29- < 32 wGA groups respectively, and 72.0 % in the 32- < 35 wGA group. Positive hospitalized-to-not-hospitalized ratios were found in all three wGA groups, progressively decreasing (from 4.0 to 1.2), with increasing wGA (p = 0.35). The percentage of hospitalized infants that were also RSV+ was also progressively decreasing (from 40.0 to 28.6 % and 18.4 %) with increasing wGA (p = 0.43). In the >12 month-age group (N = 32), there was positive hospitalized-to-not-hospitalized ratio only in the <29 wGA group with a low RSV+ frequency (< 29 %) in all wGA groups. In the <= 12 month-age group, 41 infants were evaluated with a <= 6 month-age and 27 with a >6-12 month-age. A positive hospitalized-to-not-hospitalized ratios was found in all wGA groups in <= 6 month-age infants, despite a low RSV+ frequency in the 29- < 32 and 32- < 35 wGA group. In the >6-12 month-age group, all infants with a <29 and 29- < 32 wGA were hospitalized with a relatively high RSV+ frequency whilst the 32- < 35 wGA group showed a negative hospitalized-to-not-hospitalized ratio with a lower RSV+ frequency. Conclusions: The hospitalized-to-not-hospitalized ratios and RSV+ frequency in the first 12 months of age in infants born prematurely confirm the vulnerability of these children for clinically important RSV infection, most notably in the <32 wGA category.
引用
收藏
页数:8
相关论文
共 43 条
  • [21] Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
    Chirico, Gaetano
    Ravasio, Roberto
    Sbarigia, Urbano
    ITALIAN JOURNAL OF PEDIATRICS, 2009, 35
  • [22] Respiratory syncytial virus (RSV) hospitalization in infants with congenital airway anomalies (CAA) in the canadian registry of palivizumab (CARESS) after prophylaxis (2005-2012)
    Mitchell, Ian
    Paes, Bosco
    Li, Abby
    Yi, Hao
    Lanctot, Krista
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [23] Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
    Sanchez-Luna, M.
    Burgos-Pol, R.
    Oyaguez, I.
    Figueras-Aloy, J.
    Sanchez-Solis, M.
    Martinon-Torres, F.
    Carbonell-Estrany, X.
    BMC INFECTIOUS DISEASES, 2017, 17
  • [24] Respiratory Syncytial Virus-Associated Hospitalization in Adults With Comorbidities in 2 European Countries: A Modeling Study
    Osei-Yeboah, Richard
    Johannesen, Caroline Klint
    Egeskov-Cavling, Amanda Marie
    Chen, Junru
    Lehtonen, Toni
    Fornes, Arantxa Urchueguia
    Paget, John
    Fischer, Thea K.
    Wang, Xin
    Nair, Harish
    Campbell, Harry
    JOURNAL OF INFECTIOUS DISEASES, 2024, 229 : S70 - S77
  • [25] The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis
    Lanctot, Krista L.
    Masoud, Shababa T.
    Paes, Bosco A.
    Tarride, Jean-Eric
    Chiu, Aaron
    Hui, Charles
    Francis, Philip L.
    Oh, Paul I.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3223 - 3237
  • [26] Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: A systematic literature review and meta-analysis
    Checchia, Paul A.
    Nalysnyk, Luba
    Fernandes, Ancilla W.
    Mahadevia, Parthiv J.
    Xu, Yingxin
    Fahrbach, Kyle
    Welliver, Robert C., Sr.
    PEDIATRIC CRITICAL CARE MEDICINE, 2011, 12 (05) : 580 - 588
  • [27] Estimating Respiratory Syncytial Virus-associated Hospitalization in the First Year of Life Among Infants Born at 32-35 Weeks of Gestation
    Ryan, Venessa M. J.
    Langley, Joanne M.
    Dodds, Linda
    Andreou, Pantelis
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (08) : 851 - 855
  • [28] Respiratory syncytial virus-associated hospitalization rates in high-risk populations: an observational comparative cohort analysis
    Resch, B.
    Puchas, C.
    Urlesberger, B.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2018, 37 (12) : 2413 - 2414
  • [29] Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005-2017)
    Paes, Bosco A.
    Saleem, Mahwesh
    Li, Abby
    Lanctot, Krista L.
    Mitchell, Ian
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2020, 39 (06) : 539 - 545
  • [30] Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey
    Oncel, Mehmet Yekta
    Mutlu, Banu
    Kavurt, Sumru
    Bas, Ahmet Yagmur
    Demirel, Nihal
    Akyol, Mesut
    Erdeve, Omer
    Dilmen, Ugur
    TURKISH JOURNAL OF PEDIATRICS, 2012, 54 (04) : 344 - 351